← FDA Drug Approvals (Drugs@FDA)

SYMFI

NDA · New Drug Application · Sponsor: MYLAN LABS LTD · Approved 2018-03-22

Drug application

FDA Application #

NDA022142

Application type

New Drug Application

Brand name

SYMFI

Generic name

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Active ingredients

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

Dosage form

TABLET

Route

ORAL

Marketing status

Prescription

Sponsor

MYLAN LABS LTD

Manufacturer

Viatris Specialty LLC

First approval

2018-03-22

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown